XTL Biopharmaceuticals Ltd ADR
Quarterly Financials
| Values in thousands | 2025-03-31 |
|---|---|
Revenue | $289 |
Gross Profit | -43 |
EBITDA | -429 |
EBIT | -479 |
Net Income | -255 |
Net Change In Cash | 289 |
Cash | 371 |
Basic Shares | 440 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $451 | $0 | $-459 |
Gross Profit | 0 | 3 | 0 | -1 |
EBITDA | -752 | -930 | -764 | -879 |
EBIT | -1,129 | -765 | -880 | |
Net Income | -6,969 | -1,027 | -1 | -1,348 |
Net Change In Cash | 0 | 451 | 0 | -459 |
Free Cash Flow | -1,025 | -1,672 | -707 | -901 |
Cash | 76 | 371 | 1,401 | 2,094 |
Basic Shares | 440 | 440 | 340 | 340 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | -$0.01 |
2025-03-31 | $0 |
2024-12-31 | -$0.11 |
2024-09-30 | -$0.04 |